Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Autoimmune Diseases
Biotech
Nektar stock doubles as phase 2b eczema trial hits endpoints
The biotech reported a phase 2 win in atopic dermatitis, sending its stock up 119% despite the data falling short of the bar set by Dupixent.
Nick Paul Taylor
Jun 24, 2025 9:20am
Otsuka's $670M pact to point Harbour's TCE to autoimmune disease
Jun 23, 2025 6:29am
Cullinan's $700M pact for BCMA bispecific to pair with other TCE
Jun 5, 2025 4:38am
After setback, Merck KGaA shows data justifying lupus ph. 3 push
May 21, 2025 9:50am
Accropeutics' TYK2/JAK1 inhibitor scores phase 2 psoriasis win
May 21, 2025 6:25am
Sanofi hands cancer drug to Innate as it pivots R&D pact focus
Apr 23, 2025 6:35am
